1. The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients 
Akhila Reddy, MD, Marieberta Vidal, MD, Saneese Stephen, PA, Karen Baumgartner, APRN, Sara Dost, MD, Ann Nguyen, MD, Yvonne Heung, MD, Simeon Kwan, DO, Angelique Wong, MD, Imelda Pangemanan, APRN, Ahsan Azhar, MD, Supakarn Tayjasanant, MD, Edenmae Rodriguez, PharmD, Jessica Waletich, PharmD, Kyu-Hyoung Lim, MD, Jimin Wu, MS, Diane Liu, MS, Janet Williams, MPH, Sriram Yennurajalingam, MD, Eduardo Bruera, MD 
Journal of Pain and Symptom Management 
Volume 54, Issue 3, Pages (September 2017)
DOI: /j.jpainsymman
Copyright © 2017 American Academy of Hospice and Palliative Medicine Terms and Conditions

2. Fig. 1
Flow chart of cancer inpatients seen by the palliative care consultation team from 2010 to 2014.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2017 American Academy of Hospice and Palliative Medicine Terms and Conditions

3. Fig. 2
Linear regression models. Net IV hydromorphone: defined as the total 24 hour IV hydromorphone dose prior to conversion to oral opioid regimen minus the total dose of IV hydromorphone used for breakthrough pain while on oral opioid regimen in the 24 hours before discharge. IV = intravenous; MEDD = morphine equivalent daily dose; CR = conversion ratio; ORR = opioid rotation ratio.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2017 American Academy of Hospice and Palliative Medicine Terms and Conditions